Patents by Inventor Junhai Xiao
Junhai Xiao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11927854Abstract: A touch panel includes a liquid crystal display body and a flexible printed circuit (FPC) electrically connected with the liquid crystal display body. The liquid crystal display body includes: sensing electrodes Rx, upper display screen glass, driving electrodes Tx, a color filter with a black frame, liquid crystals, a thin-film transistor drive array and lower display screen glass, where the liquid crystals are filled between the color filter with the black frame and the thin-film transistor drive array; and the liquid crystal display body comprises special-shaped regions at a lower edge of two sides of the liquid crystal display body.Type: GrantFiled: May 16, 2023Date of Patent: March 12, 2024Assignee: ZHEJIANG CHANGXING HELI OPTOELECTRONICS TECHNOLOGY CO., LTD.Inventors: Bin Xiao, Guohua Liu, Rao Huang, Junhai He
-
Publication number: 20230303494Abstract: The present invention relates to a benzylamine derivative, a preparation method therefor and use thereof, and in particular, to a benzylamine derivative as represented by general formula (I), or a pharmaceutically acceptable stereoisomer, salt, solvate or prodrug thereof, which has a strong binding capability with human PD-L1, can obviously inhibit the interaction of PD-1/PD-L1, and has significant anti-tumor efficacy in vivo. Therefore, the present invention also relates to a preparation method for the benzylamine derivative and use thereof in preparing a drug for treating PD-1/PD-L1-related diseases.Type: ApplicationFiled: July 28, 2021Publication date: September 28, 2023Inventors: Junhai XIAO, Song LI, Jialin GUO, Wu ZHONG, Longlong LUO, Zhibing ZHENG, Xinbo ZHOU, Xingzhou LI, Ruiyuan CAO, Shiyong FAN, Dian XIAO, Fei XIE, Wei LI
-
Patent number: 11447463Abstract: The present invention provides a compound of a general formula I, a stereomeride, pharmaceutically acceptable salt or a solvate thereof, a preparation method thereof, and usages in preparing medicines for preventing and/or treating diseases or symptoms caused by drug-resistant tumors or drug-resistant bacteria and in preparing medicines for preventing and/or treating diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection. Preferably, the diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection are diseases or symptoms caused by a heat shock protein 70 (Hsp70). The compound in the present invention is used for overcoming a difficult problem of drug resistance of tumors, improves the effect of tumor treatment, and provides a new medical strategy for clinical tumor treatment.Type: GrantFiled: April 9, 2019Date of Patent: September 20, 2022Assignee: Institute of Pharmacology and Toxicology Academy of Millitary Medical Sciences P.L.A. ChinaInventors: Wu Zhong, Song Li, Yanqun Zeng, Junhai Xiao, Xinbo Zhou, Zhibing Zheng, Xingzhou Li, Xiaokui Wang
-
Patent number: 11180463Abstract: The present invention pertains to field of pharmaceutical chemicals, and relates to thiazole inner salt compounds, preparation methods and uses thereof. Specifically, the present invention relates to a compound of Formula I, hydrates or pharmaceutically acceptable salts thereof. The compound of Formula I of the present invention is a potent cross-linking protein cleavage agent, has a stable structure, good physical and chemical properties, and good pharmacological activities, and is suitable for large scale production to obtain samples with stable, controllable and reliable quality, thereby being suitable for pharmaceutical development.Type: GrantFiled: April 12, 2019Date of Patent: November 23, 2021Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Wu Zhong, Shuang Cao, Lili Wang, Zhibing Zheng, Junhai Xiao, Xinbo Zhou
-
Publication number: 20210261505Abstract: Provided are a linker represented by Formula I or I?, an antibody-drug conjugate containing the same, and use of thereof, a pharmaceutical composition comprising the antibody-drug conjugate, and use of the antibody-drug conjugate for treating and/or preventing a disease.Type: ApplicationFiled: August 15, 2019Publication date: August 26, 2021Inventors: Xinbo ZHOU, Yanming WANG, Shiyong FAN, Song LI, Wu ZHONG, Junhai XIAO, Zhibing ZHENG, Xingzhou LI, Dian XIAO, Yunde XIE, Xiaokui WANG, Ruiyuan CAO
-
Publication number: 20210205464Abstract: The present application relates to a linker containing arylnitro, an antibody-drug conjugate the linker and use of the linker, as well as a pharmaceutical composition comprising the antibody-drug conjugate and use of the antibody-drug conjugate for treatment and/or prevention of a disease.Type: ApplicationFiled: August 28, 2019Publication date: July 8, 2021Inventors: Xinbo ZHOU, Yanming WANG, Song LI, Wu ZHONG, Shiyong FAN, Dian XIAO, Junhai XIAO, Zhibing ZHENG, Xingzhou LI, Yunde XIE, Ruiyuan CAO, Xiaokui WANG
-
Patent number: 10759822Abstract: Disclosed in the present invention is a compound of Formula (I), a geometric or optical isomer, a pharmaceutically acceptable salt, a solvate or a polymorph thereof. Also disclosed in the present invention is a composition comprising the compound of Formula (I), the geometric or optical isomer, the pharmaceutically acceptable salt, the solvate or the polymorph thereof. Also disclosed in the present invention is a use of the compound of Formula (I), the geometric or optical isomer, the pharmaceutically acceptable salt, the solvate or the polymorph thereof in the treatment of a disease or disorder such as a hypoglutamatergic condition, a neurodegenerative disease or respiratory depression, particularly in the treatment of a disease or disorder associated with AMPA receptor.Type: GrantFiled: April 11, 2017Date of Patent: September 1, 2020Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Xinbo Zhou, Dian Xiao, Wu Zhong, Junhai Xiao, Zhibing Zheng, Xingzhou Li, Yunde Xie, Xiaokui Wang
-
Patent number: 10647690Abstract: The present invention relates to a 2,3-epoxy succinyl derivative, a preparation method and a use thereof, in particular, the present invention relates to a compound represented by Formula (1), a racemate or an optical isomer thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof. The compound according to the present invention has good inhibitory activity and/or selectivity against cathepsin, especially Cathepsin B, can be used in the treatment of multiple diseases associated with cathepsin, for example, osteoporosis, rheumatoid arthritis and osteoarthritis that are associated with Cathepsin K, Ebola virus infection, a degenerative disease and an autoimmune disease that are associated with Cathepsin L, S, especially Cathepsin B-related tumor diseases, such as gastric cancer, cervical cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, colon cancer, neuroglioma, and melanoma.Type: GrantFiled: March 2, 2017Date of Patent: May 12, 2020Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Junhai Xiao, Xiaoye Zhang, Hongliang Wang, Wu Zhong, Zhibing Zheng, Yunde Xie, Xingzhou Li, Xinbo Zhou, Xiaokui Wang
-
Patent number: 10611742Abstract: The present invention relates to a compound represented by Formula I, a racemate or optical isomer thereof, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof, a pharmaceutical composition comprising the compound, and a use thereof in the manufacture of a medicament for preventing and/or treating a disease or disorder associated with a viral infection.Type: GrantFiled: November 24, 2016Date of Patent: April 7, 2020Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Junhai Xiao, Libao Xu, Ruiyuan Cao, Fangyuan Cao, Hongliang Wang, Wu Zhong, Zhibing Zheng, Yunde Xie, Xingzhou Li, Xinbo Zhou, Xiaokui Wang
-
Publication number: 20190233390Abstract: The present invention provides a compound of a general formula I, a stereomeride, pharmaceutically acceptable salt or a solvate thereof, a preparation method thereof, and usages in preparing medicines for preventing and/or treating diseases or symptoms caused by drug-resistant tumors or drug-resistant bacteria and in preparing medicines for preventing and/or treating diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection. Preferably, the diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection are diseases or symptoms caused by a heat shock protein 70 (Hsp70). The compound in the present invention is used for overcoming a difficult problem of drug resistance of tumors, improves the effect of tumor treatment, and provides a new medical strategy for clinical tumor treatment.Type: ApplicationFiled: April 9, 2019Publication date: August 1, 2019Applicant: Institute of Pharmacology and Toxicology Academy of Millitary Medical Sciences P.L.A. ChinaInventors: Wu ZHONG, Song Li, Yanqun Zeng, Junhai Xiao, Xinbo Zhou, Zhibing Zheng, Xingzhou Li, Xiaokui Wang
-
Publication number: 20190233383Abstract: The present invention pertains to field of pharmaceutical chemicals, and relates to thiazole inner salt compounds, preparation methods and uses thereof. Specifically, the present invention relates to a compound of Formula I, hydrates or pharmaceutically acceptable salts thereof. The compound of Formula I of the present invention is a potent cross-linking protein cleavage agent, has a stable structure, good physical and chemical properties, and good pharmacological activities, and is suitable for large scale production to obtain samples with stable, controllable and reliable quality, thereby being suitable for pharmaceutical development.Type: ApplicationFiled: April 12, 2019Publication date: August 1, 2019Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song LI, Wu ZHONG, Shuang CAO, Lili WANG, Zhibing ZHENG, Junhai XIAO, Xinbo ZHOU
-
Patent number: 10335417Abstract: The invention belongs to the technical field of medicines. In particular, the invention relates to a thiazideamide derivative compound or a pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt or solvate thereof, a method for preparing the compound or a pharmaceutically acceptable salt or solvate thereof, and a use of the compound or a pharmaceutically acceptable salt or solvate thereof. For example, the compound or a pharmaceutically acceptable salt or solvate thereof according to the invention can be used to prevent and/or treat a neurodegenerative disease or a neuropathic disease caused by a physical trauma or a related disease.Type: GrantFiled: June 28, 2016Date of Patent: July 2, 2019Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Junhai Xiao, Boqun Lyu, Hongqiang Wang, Wu Zhong, Lili Wang, Zhibing Zheng, Yunde Xie, Xinbo Zhou, Xingzhou Li, Xiaokui Wang
-
Patent number: 10301279Abstract: The present invention provides a compound of a general formula I, a stereomeride, pharmaceutically acceptable salt or a solvate thereof, a preparation method thereof, and usages in preparing medicines for preventing and/or treating diseases or symptoms caused by drug-resistant tumors or drug-resistant bacteria and in preparing medicines for preventing and/or treating diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection. Preferably, the diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection are diseases or symptoms caused by a heat shock protein 70 (Hsp70). The compound in the present invention is used for overcoming a difficult problem of drug resistance of tumors, improves the effect of tumor treatment, and provides a new medical strategy for clinical tumor treatment.Type: GrantFiled: October 26, 2017Date of Patent: May 28, 2019Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Wu Zhong, Song Li, Yanqun Zeng, Junhai Xiao, Xinbo Zhou, Zhibing Zheng, Xingzhou Li, Xiaokui Wang
-
Publication number: 20190077821Abstract: Disclosed in the present invention is a compound of Formula (I), a geometric or optical isomer, a pharmaceutically acceptable salt, a solvate or a polymorph thereof. Also disclosed in the present invention is a composition comprising the compound of Formula (I), the geometric or optical isomer, the pharmaceutically acceptable salt, the solvate or the polymorph thereof. Also disclosed in the present invention is a use of the compound of Formula (I), the geometric or optical isomer, the pharmaceutically acceptable salt, the solvate or the polymorph thereof in the treatment of a disease or disorder such as a hypoglutamatergic condition, a neurodegenerative disease or respiratory depression, particularly in the treatment of a disease or disorder associated with AMPA receptor.Type: ApplicationFiled: April 11, 2017Publication date: March 14, 2019Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song LI, Xinbo ZHOU, Dian XIAO, Wu ZHONG, Junhai XIAO, Zhibing ZHENG, Xingzhou LI, Yunde XIE, Xiaokui WANG
-
Publication number: 20190062290Abstract: The present invention relates to a 2,3-epoxy succinyl derivative, a preparation method and a use thereof, in particular, the present invention relates to a compound represented by Formula (1), a racemate or an optical isomer thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof. The compound according to the present invention has good inhibitory activity and/or selectivity against cathepsin, especially Cathepsin B, can be used in the treatment of multiple diseases associated with cathepsin, for example, osteoporosis, rheumatoid arthritis and osteoarthritis that are associated with Cathepsin K, Ebola virus infection, a degenerative disease and an autoimmune disease that are associated with Cathepsin L, S, especially Cathepsin B-related tumor diseases, such as gastric cancer, cervical cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, colon cancer, neuroglioma, and melanoma.Type: ApplicationFiled: March 2, 2017Publication date: February 28, 2019Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song LI, Junhai XIAO, Xiaoye ZHANG, Hongliang WANG, Wu ZHONG, Zhibing ZHENG, Yunde XIE, Xingzhou LI, Xinbo ZHOU, Xiaokui WANG
-
Patent number: 10196346Abstract: The present invention pertains to the field of pharmaceutical chemicals, and relates to a substituted acethydrazide derivative, preparation method and use thereof; preferably, relates to a compound of Formula I or a pharmaceutically acceptable salt thereof. The compound of the present invention or a pharmaceutically acceptable salt thereof can effectively inhibit proline hydroxylase, stabilize HIF-?, particularly HIF-1?, and has potency in the manufacture of a medicament for treatment and/or prophylaxis and/or adjuvant therapy of anemia, acute ischemic reperfusion injury.Type: GrantFiled: November 20, 2017Date of Patent: February 5, 2019Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Junhai Xiao, Lili Wang, Long Long, Wei Li, Haoming Luo, Feifei Li, Wu Zhong, Zhibing Zheng, Yunde Xie, Xingzhou Li, Xinbo Zhou, Xiaokui Wang, Ruiyuan Cao
-
Patent number: 10196411Abstract: The invention relates to tizoxanide phosphate or alkane sulfonate compounds represented by Formula I, and pharmaceutically acceptable salts thereof, isomers thereof, hydrates thereof or solvates thereof, and pharmaceutical applications of the compounds.Type: GrantFiled: December 11, 2015Date of Patent: February 5, 2019Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Xingzhou Li, Wu Zhong, Zhibing Zheng, Junhai Xiao, Xinbo Zhou, Yunde Xie, Xiaokui Wang, Lili Wang, Wei Chen, Fei Xie
-
Publication number: 20180370928Abstract: The present invention relates to a compound represented by Formula I, a racemate or optical isomer thereof, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof, a pharmaceutical composition comprising the compound, and a use thereof in the manufacture of a medicament for preventing and/or treating a disease or disorder associated with a viral infection.Type: ApplicationFiled: November 24, 2016Publication date: December 27, 2018Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song LI, Junhai XIAO, Libao XU, Ruiyuan CAO, Fangyuan CAO, Hongliang WANG, Wu ZHONG, Zhibing ZHENG, Yunde XIE, Xingzhou LI, Xinbo ZHOU, Xiaokui WANG
-
Patent number: 10160767Abstract: The present invention pertains to the field of pharmaceutical chemicals, and relates to a rapamycin derivative of Formula I, and a preparation method, pharmaceutical composition and use thereof. The compounds of the present invention overcome the defects of rapamycin in terms of water solubility and metabolic properties, and some of the compounds have an in vitro anti-tumor activity superior to rapamycin, have less toxicity to normal cells than rapamycin, and have very good druggability.Type: GrantFiled: June 3, 2015Date of Patent: December 25, 2018Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Wu Zhong, Song Li, Shuang Cao, Ruiyuan Cao, Junhai Xiao, Xinbo Zhou, Xingzhou Li
-
Patent number: 10131643Abstract: The invention relates to a tizoxanide carbamate compound of Formula I and a pharmaceutically acceptable salt, a hydrate or a solvate thereof, and their pharmaceutical use.Type: GrantFiled: July 4, 2014Date of Patent: November 20, 2018Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Xingzhou Li, Wu Zhong, Zhibing Zheng, Junhai Xiao, Xinbo Zhou, Yunde Xie, Xiaokui Wang, Lili Wang, Wei Chen, Fei Xie